00 / 00
From its founding in 1904 as one of the nation’s first cancer hospitals, Fox Chase Cancer Center’s legacy continues with a broad range of nationally competitive basic, translational, and clinical research as well as special programs in cancer prevention, detection, survivorship and community outreach.
In 1974, Fox Chase Cancer Center was one of the first centers to earn the comprehensive designation from the National Cancer Institute, the federal government agency responsible for leading the nation’s cancer enterprise. Fox Chase physicians and researchers are frequently involved in setting new guidelines for breakthrough medicine and comprehensive care.
In 1995, Fox Chase Cancer Center became a founding member of the National Comprehensive Cancer Network, an organization of the world’s leading cancer centers dedicated to setting acceptable standards of best clinical practice in oncology.
In 2000, Fox Chase Cancer Center received Magnet Designation for Nursing Excellence from the American Nurses Credentialing Center, and in 2018 the center became the first cancer hospital in the country to achieve this designation five consecutive times.
Fox Chase Cancer Center became part of the Temple University Health System in 2012.
Fox Chase Cancer Center is the home of Nobel laureates and was the center of the research that identified the Philadelphia chromosome. This discovery led to the development of the field of cancer genetics and the development of Gleevec, which has extended the lives of thousands of patients with chronic myeloid leukemia.
Fox Chase Nobel Laureates include:
Fox Chase Cancer Center is routinely designated as a US News best hospital, has multiple nationally recognized best doctors, and was recognized by Consumer Reports for best surgical outcomes.
This history informs our unique “Fox Chaseness,” a term coined to describe the special, intangible experience of being a patient at Fox Chase.